<DOC>
	<DOCNO>NCT01545440</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study ass efficacy safety lebrikizumab patient asthma whose disease remain uncontrolled despite daily therapy inhale corticosteroid second controller medication . Patients randomize 1:1:1:1 ratio receive double-blind treatment subcutaneous lebrikizumab ( `` high '' , `` middle '' , `` low '' dose ) placebo every 4 week 52 week , addition standard-of-care therapy . This follow 52-week double-blind active treatment extension . The anticipated time study treatment 104 week . There safety follow-up 24 week last dose study drug patient .</brief_summary>
	<brief_title>A Study Lebrikizumab Patients Whose Asthma Uncontrolled With Inhaled Corticosteroids A Second Controller Medication ( LUTE )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient , 18 75 year age Visit 1 Asthma diagnosis &gt; /= 12 month prior start screen ( Visit 1 ) Bronchodilator response screen Prebronchodilator FEV1 40 % 80 % predict screen On ICS ( inhaled corticosteroid ) 5002000 mcg/day fluticasone propionate DPI equivalent &gt; /= 6 month prior start screen ( Visit 1 ) anticipate change throughout study On eligible second controller medication ( LABA , LAMA , LTRA theophylline within prescribed dose range ) Uncontrolled asthma define protocol screen period time randomization Chest Xray compute tomography ( CT ) scan obtain within 12 month prior screen chest Xray screen period confirm absence lung disease Demonstrated adherence controller medication screen period History severe allergic anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Use zileuton roflumilast within 6 month prior screen Maintenance oral corticosteroid therapy , define daily alternate day oral corticosteroid maintenance therapy within 3 month prior Visit 1 Treatment systemic ( oral , intravenous intramuscular ) corticosteroid within 4 week prior Visit 1 Major episode infection within 4 week prior Visit 1 treatment oral antibiotic within 2 week prior Visit 1 Active parasitic infection within 6 month prior Visit 1 Active tuberculosis require treatment within 12 month prior Visit 1 Known immunodeficiency , include , limited , HIV infection Evidence acute chronic hepatitis know liver cirrhosis History cystic fibrosis , chronic obstructive pulmonary disease , and/or clinically significant lung disease asthma Known malignancy current evaluation potential malignancy Current smoker former smoker history &gt; 10 pack year History alcohol , drug chemical abuse Initiation change allergen immunotherapy within 3 month prior Visit 1 Use biologic therapy include omalizumab 6 month prior Visit 1 Receipt live/attenuated vaccine within 4 week prior Visit 1 Pregnant lactate woman Body mass index ( BMI ) &gt; 38 kg/m2 Body weight &lt; 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>